About Me

My Photo
Initially diagnosed June 4, 2009 Invasive Ductal Carcinoma Stage II,Grade II tumor size: 2-3 cm node positive ER/PR postive HER2 Neu - negative Current Diagnosis: Metastatic Invasive Ductal Carcinoma Grade 3 Mets: Scalp/skin, Liver, Spine, Bone ER/PR + HER2/NEU -

Search This Blog

Sunday, July 12, 2009

Research on the Chemo Treatment Plan I'm Receiving

From the
Adjuvant and Neoadjuvant Chemotherapy for Breast Cancer
San Antonio Breast Cancer Symposium 2005
Date: December 8-11, 2005
Location: San Antonio, Texas
Author: Lee Schwartzberg, MD, FACP

Full text here: http://professional.cancerconsultants.com/conference_sabcs_2005.aspx?id=35828

"Adjuvant Chemotherapy - Refining the Role of Taxanes

Several large adjuvant trials evaluating the worth of taxanes were presented this year. The most eagerly awaited was ECOG-1199, testing two different hypotheses in a 2 x 2 design: First, whether there was a clinical advantage to Taxotere vs. Taxol and, secondly, whether weekly or every-three-week scheduling of taxanes was superior.[7] Five thousand women were randomized to one of four arms, 88% had lymph node positive disease and 20% were HER-2 positive. Taxol given every three weeks was considered the standard arm and was compared to Taxol weekly or Taxotere given weekly or every three weeks as the experimental arms. At a median follow up of 47 months at this fourth interim analysis there is no significant difference between Taxol and Taxotere (p = 0.83) nor between dose schedules weekly vs. every three weeks. However, an explanatory analysis revealed that weekly Taxol vs. every-three-week Taxol was 20% better, p = 0.06. The Taxotere arms did not differ significantly from Taxol every three weeks but had more Grade III and IV hematologic toxicity. So far the findings of E-1199 provide no reason to alter our current approaches to adjuvant chemotherapy of breast cancer.

A German adjuvant study compared 6 cycles of FEC to 4 cycles of FEC plus eight weeks of Taxol in node positive patients.[8] At 46 months of median follow up, FEC plus Taxol had a DFS of 85% vs. 79% for FEC alone for an HR of 0.063 (p = 0.006). Overall survival is numerically better for FEC plus taxol, 94% vs. 92% for FEC, which is not yet statistically significant. Toxicity was manageable in both arms."


Post a Comment

Disqus for Aymz Blog